Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

4D pharma plc appoints independent Non-Executive Directors

4D pharma plc
Posted on: 08 Jan 19

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as independent Non-Executive Directors with immediate effect.

Ed Baracchini, PhD, was previously the Chief Business Officer at Xencor Inc. where he led strategic alliances and licensing.  During his time at Xencor he negotiated license agreements with Novartis ($2.6B: immune-oncology bispecific antibodies), Novo Nordisk ($600M: drug discovery collaboration), Amgen ($500M: option and development agreement autoimmune disease antibody) among numerous others.  Prior to that he served as SVP Business Development for Metabasis Therapeutics.

Professor Dr. med. Axel Glasmacherwas until recently Senior Vice President and Head of the Global Clinical Research and Development Hematology Oncology at Celgene, where he has worked in various global roles for more than ten years.  His work at Celgene led to the approvals of Revlimid®, Idhifa®, and Vidaza® (haematological cancers).  He also worked on the PD-L1 inhibitor durvalumab.  Prior to Celgene, Professor Glasmacher worked within the fields of hematology-oncology at the University Hospital in Bonn. 

Duncan Peyton, 4D’s Chief Executive Officer, commented: “We welcome Axel and Ed to our Board with great pleasure.  Their collective experience will strengthen our commercial and therapeutic focus, as 4D accelerates development of its extensive pipeline in cancer and other immunological diseases.”


About 4D

Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as bacteria, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect.  All of 4D’s live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.  4D has a phase II study in Irritable Bowel Syndrome running and has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease.  The Company plans to commence three additional clinical studies in 2019.


For more information:

Editor's Details

Fay Weston
4D pharma plc
+44 (0) 7990381713

Last updated on: 08/01/2019

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.